Imaging Pain Relief in Osteoarthritis (IPRO): protocol of a double-blind randomised controlled mechanistic study assessing pain relief and prediction of duloxetine treatment outcome

Reckziegel, Diane, Bailey, Helen, Cottam, William J., Tench, Christopher R., Mahajan, Ravi P., Walsh, David A., Knaggs, Roger and Auer, Dorothee P. (2017) Imaging Pain Relief in Osteoarthritis (IPRO): protocol of a double-blind randomised controlled mechanistic study assessing pain relief and prediction of duloxetine treatment outcome. BMJ Open, 7 (6). e014013/1-e014013/7. ISSN 2044-6055

Full text not available from this repository.

Abstract

Introduction: Osteoarthritis (OA) pain is a major cause of long-term disability and chronic pain in the adult population. One in five patients does not receive satisfactory pain relief, which reflects the complexity of chronic pain and the current lack of understanding of mechanisms of chronic pain. Recently, duloxetine has demonstrated clinically relevant pain relief, but only in half of treated patients with OA. Here the aim is to investigate the neural mechanisms of pain relief and neural signatures that may predict treatment response to duloxetine in chronic knee OA pain.

Methods and analysis: This is an ongoing single-centre randomised placebo-controlled mechanistic study (2:1 [placebo] allocation), using a multi-modal neuroimaging approach, together with psychophysiological [quantitative sensory testing], genetics and questionnaire assessments. Eighty-one subjects with chronic knee OA pain are planned to power for between group comparisons (placebo, duloxetine-responder, and duloxetine-non-responder). Participants have a baseline assessment and, following six weeks of duloxetine (30mg for two weeks, then 60mg for four weeks), a follow-up evaluation. Brain imaging is performed at 3T with blood-oxygen-level dependent functional magnetic resonance imaging at rest and during pin-prick nociceptive stimulation for main outcome assessment; arterial spin labelling and structural imaging (T1- weighted) for secondary outcome assessment. Questionnaires evaluate pain, negative affect, quality of sleep and cognition.

Ethics and dissemination: The study has been approved by the East Midlands – Nottingham 2 research ethics committee (18/EM/0189) and is being carried out under the principles of the Declaration of Helsinki (64th, 2013) and Good Clinical Practice standards. Results will be disseminated in peer-reviewed journals and at scientific conferences.

Item Type: Article
RIS ID: https://nottingham-repository.worktribe.com/output/844646
Keywords: Osteoarthritis pain, magnetic resonance imaging, fMRI, analgesia, duloxetine, antidepressant
Schools/Departments: University of Nottingham, UK > Faculty of Medicine and Health Sciences > School of Medicine > Division of Clinical Neuroscience
University of Nottingham, UK > Faculty of Medicine and Health Sciences > School of Medicine
University of Nottingham, UK > Faculty of Medicine and Health Sciences > School of Medicine > Division of Rheumatology, Orthopaedics and Dermatology
University of Nottingham, UK > Faculty of Science > School of Pharmacy
University of Nottingham, UK > Faculty of Medicine and Health Sciences > School of Medicine > Units > Radiology and Imaging Sciences
Identification Number: https://doi.org/10.1136/bmjopen-2016-014013
Depositing User: Eprints, Support
Date Deposited: 05 May 2017 12:34
Last Modified: 04 May 2020 18:33
URI: https://eprints.nottingham.ac.uk/id/eprint/42561

Actions (Archive Staff Only)

Edit View Edit View